Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>Dmpk</i>gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice

13 Aug 2016

Abstract excerpt

Myotonic dystrophy type 1 (DM1) is a genetic disorder in which dominant-active DM protein kinase (DMPK) transcripts accumulate in nuclear foci, leading to abnormal regulation of RNA processing. A leading approach to treat DM1 uses DMPK-targeting antisense oligonucleotides (ASOs) to reduce levels of toxic RNA. However, basal levels of DMPK protein are reduced by half in DM1 patients. This raises concern that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Genetic Neurodegenerative Diseases
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27522499
DOI: 10.1093/hmg/ddw266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>Dmpk</i>gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in micePMID 27522499Read ↗

Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3′UTR RNASemantic proximity Read ↗

Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).Semantic proximity Read ↗

Targeting nuclear RNA for in vivo correction of myotonic dystrophy.Semantic proximity Read ↗

Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice.Semantic proximity Read ↗

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1Semantic proximity Read ↗

Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1Semantic proximity Read ↗

MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model.Semantic proximity Read ↗

Characterisation of <i>DMPK</i> and MBNL1 expression in cell models of Myotonic Dystrophy: A platform for drug screeningSemantic proximity Read ↗

Perspectives on gene therapy in myotonic dystrophy type 1.Semantic proximity Read ↗

Progressive cardiac phenotypes and reduced reversibility from long-term CUGexp RNA expression in a DM1 mouse model.Semantic proximity Read ↗

Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1Semantic proximity Read ↗

Myotonic dystrophy: approach to therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.